U.S. STOCKS Alnylam, Affirm, Synovus Financial
Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: https://refini.tv/3LI4BU7
The Morning News Call newsletter: https://refini.tv/3dKUyB8
The Nasdaq was set to open lower on Monday after Nvidia and other chip stocks remained under selling pressure, with investors on tenterhooks as a key inflation print this week could further shape bets over the timing and quantum of rate cuts. .N
At 9:05 ET, Dow e-minis 1YMc1 were up 0.21% at 39,668. S&P 500 e-minis ESc1 were down 0.06% at 5,531, while Nasdaq 100 e-minis NQc1 were down 0.31% at 19,921.25.
The top three NYSE percentage gainers premarket .PRPG.NQ:
** Terreno Realty <TRNO.N>, up 20.7%
** V2X <VVX.N>, up 11.2%
** RXO <RXO.N>, up 9.4%
The top three NYSE percentage losers premarket .PRPL.NQ:
** HCI Group <HCI.N>, down 16.6%
** Eagle Materials <EXP.N>, down 12.5%
** ATI Physical Therapy <ATIP.N>, down 12.4%
The top two Nasdaq percentage gainers premarket .PRPG.O:
** Agrify <AGFY.O>, up 135.7%
** Alimera Sciences <ALIM.O>, up 76.5%
The top three Nasdaq percentage losers premarket .PRPL.O:
** eFFECTOR Therapeutics <EFTR.O>, down 73.1%
** G1 Therapeutics <GTHX.O>, down 43.5%
** American Rebel Holdings <AREB.O>, down 26.3%
** ResMed RMD.N: down 9.1% premarket
BUZZ - Slumps on Lilly's sleep apnea trial for weight-loss drug nL4N3IM0O4
** RXO RXO.N: up 9.4% premarket
BUZZ - To buy Coyote logistics from UPS; shares jump nL4N3IM0K4
** Coinbase Global COIN.O: down 3.9% premarket
** Bitfarms BITF.O: down 6.8% premarket ** Riot Platforms RIOT.O: down 4.0% premarket
** Marathon Digital Holdings MARA.O: down 4.9% premarket
BUZZ - Crypto stocks decline tracking a fall in Bitcoin nL4N3IM0M7
** Carrier Global CARR.N: up 2.3% premarket
BUZZ - Rises after Citi upgrades to 'buy', lifts PT nL4N3IM0NA
** Micron Technology MU.O: up 2.1% premarket
BUZZ - Citi raises PT on Micron ahead of earnings, shares up nL4N3IM0MG
** Alnylam Pharmaceuticals ALNY.O: up 35.8% premarket
BUZZ - Jumps as heart disease drug succeeds in late-stage trial nL4N3IM0U0
** Affirm Holdings AFRM.O: up 3.3% premarket
BUZZ - Rallies after Goldman upgrades to "buy" nL1N3IM0HL
** Synovus Financial SNV.N: up 1.3% premarket
BUZZ - Rises after Barclays upgrades to 'overweight', raises PT nL4N3IM0QN
** Arrowhead Pharmaceuticals ARWR.O: up 3.9% premarket
BUZZ - Climbs on positive preclinical data for obesity treatment nL4N3IM0XK
(Compiled by Rajarshi Roy and Anuja Bharat Mistry in Bengaluru)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
